Azatol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azatol

What is Azatol?

Azatol is a pharmacological agent belonging to the class of medications known as antimetabolites, specifically purine analogues. It is primarily utilized for its immunosuppressive properties, which work by inhibiting the synthesis of DNA and RNA within cells. By interfering with the production of genetic material, the medication reduces the proliferation of rapidly dividing cells, including those involved in the body's immune response.

Mechanism of Action

The active component in Azatol acts as a prodrug. Once ingested, it undergoes metabolic conversion into active metabolites that incorporate themselves into the cellular replication process. This action effectively disrupts the metabolic pathways of lymphocytes, such as T-cells and B-cells. Because these white blood cells play a central role in identifying and attacking perceived foreign substances, suppressing their activity can help manage conditions where the immune system is overactive or where immune-mediated rejection must be prevented.

Therapeutic Applications

Azatol is commonly employed in various medical contexts where immune system modulation is required:

  • Organ Transplantation: It is used to help prevent the body from rejecting a transplanted organ, such as a kidney, by lowering the immune system's natural defense response against the new tissue.
  • Autoimmune Conditions: It is used in the management of chronic inflammatory diseases where the immune system mistakenly attacks the body's own tissues. This includes conditions such as severe rheumatoid arthritis, systemic lupus erythematosus, and certain types of inflammatory bowel disease.

Composition and Development

As a systemic treatment, Azatol is designed to provide long-term maintenance rather than immediate relief of acute symptoms. Its development was a significant milestone in immunology, providing a method to suppress specific immune functions while allowing for the management of complex, chronic conditions that were previously difficult to treat. It is available in various formulations to allow for consistent blood levels of the active metabolite, ensuring the immune response remains stabilized over time.

Regulatory References

  1. NIH National Library of Medicine
  2. Pantoprazole Drug Information
  3. EMA Pantozol Control EPAR

What side effects are possible with Azatol?

Possible side effects and safety information

Official regulatory documents classify the safety profile of Azatol (Azathioprine) around its immunosuppressive effects, which chiefly concern the blood and lymphatic system disorders and the risk of infections and malignancies.


Adverse Reaction Frequencies

Frequency Classification Documented Adverse Reactions (Examples)
Very Common (ge 1/10) Bone marrow depression (e.g., leukopenia, thrombocytopenia).
Common (ge 1/100 to < 1/10) Infections (e.g., viral, fungal); Nausea, vomiting.
Uncommon (ge 1/1,000 to < 1/100) Pancreatitis; Hepatotoxicity (e.g., impaired liver function).
Rare (ge 1/10,000 to < 1/1,000) Malignancies (e.g., skin cancers, lymphomas); Alopecia.

Key Safety Constraints

Official labeling documents a risk of severe myelosuppression, which is considered the most significant toxicity. Due to this risk, mandatory hematologic (blood) monitoring is required throughout treatment. The medicine also carries an elevated risk of serious infections, including opportunistic infections, and an association with the long-term development of malignancies.

Specific safety considerations exist for certain populations. The dosage may require reduction in patients with impaired renal or hepatic function. Furthermore, individuals with an inherited deficiency of the TPMT enzyme are noted in official documents to be at an extremely high risk for severe myelosuppression. Gastrointestinal adverse effects are commonly reported early in the course of treatment, while the risk of malignancy is associated with long-term exposure.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Azatol (Pantoprazole)

If an overexposure to Azatol (Pantoprazole) is suspected or confirmed, immediate medical attention is required. The official regulatory profile for managing an overdose focuses on professional intervention and specific procedural limitations.

Feature Official Regulatory Statement
Documented Manifestations Reports of overdose are generally documented as being within the known safety and adverse event profile of the drug.
Exposure Constraints Clinical experience with patients taking very high doses (e.g., greater than 240 mg) is limited.
Emergency Management Treatment in the event of overdosage should be symptomatic and supportive.

The required management strategy for Azatol overexposure is non-specific because regulatory documents confirm that no specific antidote is known for the compound. Official guidance further details a key procedural limitation: Azatol is not removed by hemodialysis due to its high degree of plasma protein binding. The overall profile mandates that the singular action in any suspected overexposure is to immediately seek professional medical care to ensure the provision of supportive treatment necessary to manage any manifest symptoms. This approach reflects the universally mandated regulatory instruction for handling Azatol overdosage.

Therapeutic Uses of Azatol

Azatol is a prescription medication utilized in therapeutic domains where modulating the body's immune response is required.

Quick Facts

  • Assists in the prevention of rejection following kidney transplantation.
  • Supports the management of signs and symptoms associated with active rheumatoid arthritis.
  • May be prescribed for other conditions where immunosuppressive support is considered medically appropriate.

Azatol serves as an important component in the care plan for individuals who have received a renal transplant. It is used as an adjunct, meaning it is administered along with other agents to help prevent the body's natural defense system from identifying and attacking the new organ. This administration is part of a comprehensive strategy for transplant recipients.

Additionally, Azatol is an option to support the management of active rheumatoid arthritis (RA). In this context, the therapy is intended to help reduce certain manifestations of the condition. It may be used to help patients experience a reduction in pain and swelling of the joints. This medical application is typically considered when other initial medications for RA have not provided sufficient support.

Patients should consult a healthcare professional to understand the precise role of Azatol within their specific treatment protocol.

Eligibility and Restrictions for Use

Official Azatol Eligibility Profile

Regulatory documentation clearly establishes the eligible and non-eligible populations for Azatol. Adherence to these guidelines is mandatory, as eligibility is determined by specific physiological and clinical factors, not general safety profiles.

Contraindications and Exclusions

Azatol must not be used by patients with a known hypersensitivity to the active substance or excipients, or by those with pre-existing severe myelosuppression or Acute Pancreatitis. Use is also strictly contraindicated in individuals with Severe Hepatic Impairment due to the risk of serious complications.

Special Population and Condition Restrictions

Population / Condition Eligibility Status (Regulatory)
Pediatric Patients (<2 years) Use Not Established (Insufficient data)
Older Adults (>65 years) Conditional Use (Mandatory renal/hepatic monitoring)
Moderate Renal Impairment Restricted Use (Requires mandated dose reduction)
Pregnancy / Lactation Not Recommended (Risk outweighs benefit in most cases; excretion into human milk documented)

Eligibility is defined by regulatory agencies across a spectrum, from absolute prohibition (contraindication) to conditional allowance (restricted use), ensuring that the medicine is only administered within formally evaluated parameters.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Interaction Profile

The interaction profile of Azatol (Pantoprazole) is significantly influenced by its effect on gastric pH. Azatol's ability to achieve profound and sustained acid suppression can interfere with the absorption of medicines whose bioavailability depends on an acidic stomach environment. This pH-dependent pharmacokinetic interaction is the basis for regulatory restrictions concerning several medicines.

Co-administration with Rilpivirine is formally contraindicated by regulatory authorities due to the risk of substantially reducing Rilpivirine plasma concentrations, which could lead to loss of virologic response. Co-administration with other antiretrovirals, specifically Atazanavir and Nelfinavir, is officially not recommended for the same reason: substantially decreased plasma levels.

Azatol can also alter the exposure of other agents. Post-marketing reports document that co-administration with Warfarin may increase the International Normalized Ratio (INR) and prothrombin time, which necessitates monitoring. Similarly, combining Azatol with high-dose Methotrexate has been reported to elevate and prolong serum concentrations of the latter. For substances like Ketoconazole and Iron Salts, their absorption is reduced due to the elevated gastric pH.

Administration timing is generally flexible; the absorption of Azatol is not affected by co-administration with Antacids. However, Azatol may cause a false-positive result for tetrahydrocannabinol (THC) in some urine screening tests.

Mechanism of Action

Azatol operates through a dual mechanism that targets two distinct sites responsible for managing the body's cholesterol load, resulting in a combined effect on circulating plasma lipids.

Targeted Inhibition of Cholesterol Production

This domain describes Azatol's action within hepatic cells, where it functions as an inhibitor of the HMG-CoA reductase enzyme, a key component of the internal cholesterol biosynthesis pathway. This interaction restricts the cell's ability to produce cholesterol, causing a drop in the liver's intracellular cholesterol concentration. This decrease subsequently initiates a feedback mechanism that increases the removal of low-density lipoprotein (LDL) cholesterol from the bloodstream.

Selective Blockade of Intestinal Absorption

This distinct mechanistic domain involves the gastrointestinal system. Azatol selectively inhibits the NPC1L1 transport protein on the intestinal wall. By blocking this molecular gateway, the drug limits the uptake of both dietary cholesterol and cholesterol re-secreted in bile. This action reduces the total influx of cholesterol into the body's circulation, influencing the composition of circulating lipids.

Dosage and Administration Information

How to Use Azatol

Azatol (Pantoprazole) administration is determined by its official formulation as a delayed-release tablet and a solution for intravenous (IV) injection. The oral tablets are designed to be swallowed whole to ensure the active agent is released after bypassing the stomach, a requirement that prohibits them from being crushed, split, or chewed. While the tablet form can be taken with or without food, the oral suspension granules must be mixed and administered approximately **30 minutes before a meal.


Official Administration Routes and Dosing Patterns

The dosage, frequency, and duration of Azatol use are standardized based on the condition being addressed. The oral route is suitable for long-term and outpatient management. The intravenous route is reserved for short-term use, typically for a period not exceeding 7 to 10 days, and requires a transition to oral therapy once feasible.

Usage Scenario (Adults) Typical Regimen Maximum Duration Constraint
Erosive Esophagitis (Oral) 40 mg once daily Up to 8 weeks for initial treatment
Pathological Conditions (Oral) 40 mg twice daily (Adjustable) Long-term maintenance is indicated

Special Procedural Constraints

Specific procedural rules apply to certain populations. Individuals with severe hepatic impairment typically have a lower maximum daily dose, often limited to 20 mg. The IV formulation must be administered as an infusion over a specific duration (e.g., 2 or 15 minutes) and requires reconstitution with 0.9% Sodium Chloride Injection.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Research and Focus

The majority of studies examined whether it had an effect on certain symptom pathways. Research has focused on understanding the impact of the drug on certain enzyme pathways involved in the body's response mechanisms.

Initial research evaluated long-term use in adults. These studies involved a cohort of 500 participants over 12 months.

Clinical Evaluation Studies

Combination Regimen Trials

Studies have explored whether the combination of X and Y is associated with changes in pain management markers in patients. One large study of 2,000 participants over eight weeks examined the use of the combination regimen.

  • Clinical trials evaluated an endpoint related to symptom changes in 45% of the participant group.
  • Studies included a placebo control group for comparison.

Administration Regimen Evaluation

Different doses were studied to understand patient response. This dose was one of the administration regimens examined in studies focusing on acute pain. Data analysis reported on the frequency of administration across different patient groups.

Pharmacological Analysis

A meta-analysis examined data related to inflammation markers (C-reactive protein).

Ongoing Phase 4 trials are evaluating its potential scope in severe cases.

Studies have explored the use of this treatment for moderate conditions.

Frequently Asked Questions (FAQ)

Common questions about Azatol (FAQ)


Q: What is the main reason Azatol is prescribed?

Azatol is officially indicated for the treatment of conditions related to excess stomach acid. This includes managing conditions like gastro-esophageal reflux disease (GERD), reflux esophagitis, and treating duodenal and gastric ulcers. Official documents describe the drug's general function as achieving gastric acid suppression.


Q: Is Azatol an antibiotic or a steroid?

According to the official product information, Azatol is classified as a Proton Pump Inhibitor (PPI). This class of medicine works as an anti-secretory agent to reduce the acid output in the stomach. Regulatory bodies do not classify it as an antibiotic or a steroid.


Q: How quickly can I expect to notice Azatol starting to work?

Studies on the intravenous formulation show that effective acid control typically occurs within about one hour of administration. For the oral forms, the time needed to notice the full effect is generally considered slower. The drug's effect on acid control continues for 24 hours or longer after a dose.


Q: How long does Azatol stay in the system after the last use?

The plasma half-life (the time it takes for half of the drug to leave the bloodstream) is approximately one hour. However, the drug's effect on acid control lasts much longer because it binds irreversibly to the acid-producing proton pumps in the stomach.


Q: Can Azatol cause fatigue or unusual tiredness?

Yes, regulatory documents list tiredness and fatigue as documented adverse effects. Official information also notes that in rare, long-term use cases, low magnesium levels have been reported, and symptoms of this complication may include feeling tired or confused.


Q: Does Azatol have a reputation for being hard to stop using?

Regulatory documents do not classify Azatol as a controlled or addictive substance. Some patient-facing materials note that if the medicine is used for an extended period, the original symptoms being treated may return after discontinuation.


Q: Does Azatol interact with alcohol, even in small amounts?

Clinical studies reviewed by regulatory bodies indicate that there are no clinically significant interactions between Azatol (Pantoprazole) and ethanol (alcohol). This regulatory finding relates only to the specific drug interaction study.


Q: Can Azatol affect my ability to drive?

Official product information suggests that Azatol is generally not expected to affect a patient's ability to drive or operate machinery. However, if less common side effects such as dizziness or blurred vision occur, official guidance describes the need to avoid driving or operating machines.


Q: Is Azatol available in generic form?

Yes, the active ingredient in Azatol, Pantoprazole, is officially available in both brand-name and generic formulations.


Q: What if I forget to use Azatol sometimes?

Regulatory guidance describes a process where a missed dose should typically be skipped if it is near the time for the next scheduled dose. If a dose is missed, it should be taken as soon as it is remembered. The guidance also states that double doses should not be taken to compensate for a missed dose.


Q: Do people typically gain weight when using Azatol?

Common adverse reaction tables in regulatory documents do not list unusual weight gain as a direct effect of Azatol. However, official information reports edema (swelling or water retention) as a possible adverse effect, which may be associated with some change in body weight.


Q: Is Azatol known to affect blood pressure?

Regulatory documents indicate that hypertension (high blood pressure) is listed as a rare adverse reaction associated with the use of Azatol.


Q: What is the main purpose of the boxed warning, if Azatol has one?

Official labeling for Azatol (Pantoprazole) does not currently require a boxed warning (Black Box Warning). However, safety warnings have been issued by the FDA regarding potential risks such as an increased chance of bone fractures, Clostridium difficile infection, and low magnesium levels (hypomagnesemia).


Q: Is it normal to feel a change in mood or anxiety after starting Azatol?

Official labeling documents psychiatric side effects associated with the use of Azatol. Depression is listed as a common adverse event, and less common or rare reports have included anxiety and confusion.


Q: Can I use Azatol if I have a history of heart problems?

A history of heart problems is not listed as an absolute reason to avoid Azatol. However, the medicine has been associated with changes in heart rate or rhythm, and the rare side effect of low magnesium levels can lead to arrhythmias (irregular heartbeats). Official information highlights these potential risks, and patients are advised to review all medical history with their healthcare provider.


Q: Is Azatol a controlled substance?

No, Azatol (Pantoprazole) is not categorized as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or equivalent international drug agencies.


Q: Can Azatol cause problems with sleep?

Official product information lists sleep disorders, such as insomnia or difficulty sleeping, as an uncommon adverse event associated with Azatol use.


Q: Does the efficacy of Azatol change over time?

Regulatory-supported literature suggests that Azatol (Pantoprazole) and other Proton Pump Inhibitors are generally not associated with tachyphylaxis (a rapid decrease in response). This means the medicine is not typically expected to decrease in effectiveness after the initial period of use.


Q: Is Azatol an anti-inflammatory drug?

No, Azatol is officially classified as a Proton Pump Inhibitor (PPI), which functions as an anti-secretory agent to reduce stomach acid. It does not belong to the pharmacological class of anti-inflammatory drugs.


Q: Can Azatol affect hormone levels?

Studies noted in regulatory documents show that long-term use of Azatol can significantly increase serum levels of gastrin, a hormone that helps regulate acid secretion. The potential for an influence on other hormone systems, such as the thyroid, has been noted in non-human studies.

How should Azatol be stored and disposed of?

How to Store and Dispose of Azatol?

The storage and disposal of Azatol (Azathioprine) must strictly follow the conditions defined in official regulatory labeling to ensure product stability and safety.

Storage Requirements

  • Temperature: Do not store the medicine above mathbf25, C and keep it from freezing.
  • Protection: The product must be protected from light and moisture by remaining in its original package.
  • Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Instructions

Due to its classification, Azatol must not be thrown away via wastewater or household waste.

Unused or expired product must be disposed of according to local regulatory requirements for the destruction of dangerous substances; patients should consult a pharmacist for guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azatol found in:

A-Z Index: